{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-167512","form_type":"8-K","ticker":"KYTX","cik":"0001994702","company_name":"Kyverna Therapeutics, Inc.","filed_at":"2026-04-22T23:59:59+00:00","discovered_at":"2026-05-14T18:02:33.359971+00:00","generated_at":"2026-05-15T04:56:45.999123+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Kyverna's miv-cel meets all endpoints in KYSA-8 SPS trial; median T25FW improvement 46% (p=0.0003)","bullets":["Single-dose miv-cel achieved statistically significant improvements across all primary and secondary endpoints at Week 16.","81% of patients achieved ≥20% improvement in T25FW; 67% of walking-aid users no longer needed assistance.","All 26 patients discontinued chronic immunotherapies through last follow-up; no high-grade CRS or ICANS observed.","Company plans to submit BLA for miv-cel in SPS; data also support potential in myasthenia gravis.","Natural history study of 153 SPS patients showed minimal improvement with current treatments, underscoring unmet need."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-167512","json":"https://secwatch.observer/filing/0001193125-26-167512.json","markdown":"https://secwatch.observer/filing/0001193125-26-167512.md","text":"https://secwatch.observer/filing/0001193125-26-167512.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1994702/000119312526167512/0001193125-26-167512-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1994702/000119312526167512/kytx-20260421.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T04:56:45.999123+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}